Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer.

Breast Cancer Res Treat · 2026 · PMC12894150 · PMID 41670749

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In age-adjusted analysis (Table 2 ), we observed a borderline significant difference in overall survival for individuals with ER low-positive disease compared to ER-negative disease (HR = 0.91, 95% CI 0.83–1.00) (Table 2 ).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.